NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 25 04:00PM ET
2.88
Dollar change
-0.02
Percentage change
-0.69
%
IndexRUT P/E- EPS (ttm)-0.95 Insider Own10.13% Shs Outstand66.52M Perf Week1.05%
Market Cap191.59M Forward P/E- EPS next Y-0.95 Insider Trans5.96% Shs Float59.79M Perf Month-18.64%
Income-45.45M PEG- EPS next Q-0.19 Inst Own34.62% Short Float28.99% Perf Quarter-15.54%
Sales0.68M P/S281.75 EPS this Y16.87% Inst Trans110.16% Short Ratio14.00 Perf Half Y2.49%
Book/sh1.25 P/B2.31 EPS next Y-19.91% ROA-50.81% Short Interest17.34M Perf Year-30.94%
Cash/sh1.38 P/C2.09 EPS next 5Y-9.85% ROE-59.51% 52W Range2.01 - 5.64 Perf YTD-33.64%
Dividend Est.- P/FCF- EPS past 5Y19.36% ROI-54.27% 52W High-48.93% Beta1.80
Dividend TTM- Quick Ratio7.08 Sales past 5Y24.32% Gross Margin40.94% 52W Low43.28% ATR (14)0.25
Dividend Ex-Date- Current Ratio7.08 EPS Y/Y TTM-2.76% Oper. Margin-7112.72% RSI (14)43.85 Volatility7.19% 8.38%
Employees33 Debt/Eq0.02 Sales Y/Y TTM40.16% Profit Margin-6645.47% Recom1.00 Target Price14.20
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-2.10% Payout- Rel Volume0.59 Prev Close2.90
Sales Surprise53.00% EPS Surprise10.71% Sales Q/Q-3.21% EarningsFeb 27 AMC Avg Volume1.24M Price2.88
SMA201.41% SMA50-19.14% SMA200-7.96% Trades Volume733,190 Change-0.69%
Date Action Analyst Rating Change Price Target Change
Sep-06-24Initiated Craig Hallum Buy $8
Jan-05-22Initiated William Blair Outperform
Dec-08-21Initiated Robert W. Baird Outperform $19
Aug-09-21Resumed Maxim Group Buy $30 → $20
Oct-22-20Initiated H.C. Wainwright Buy $27
Oct-08-20Initiated Piper Sandler Overweight $25
Apr-24-25 10:01AM
Apr-23-25 04:05PM
04:05PM
Apr-15-25 04:10PM
04:05PM
03:57PM Loading…
Mar-26-25 03:57PM
Mar-08-25 07:33AM
Feb-27-25 04:05PM
Feb-26-25 08:12AM
Feb-24-25 04:05PM
Feb-20-25 04:05PM
Dec-26-24 09:00AM
Dec-20-24 12:52PM
Dec-18-24 11:12AM
Dec-14-24 06:50AM
07:19AM Loading…
Dec-11-24 07:19AM
Dec-10-24 07:20AM
06:00AM
Nov-19-24 08:00AM
Nov-07-24 04:05PM
Oct-30-24 04:30PM
Aug-08-24 04:05PM
Aug-01-24 04:05PM
May-29-24 04:05PM
May-13-24 04:05PM
May-09-24 12:15PM
May-07-24 06:00AM
May-02-24 09:54PM
05:45PM
04:05PM
04:05PM Loading…
Apr-25-24 04:05PM
Apr-08-24 04:05PM
Apr-01-24 08:50AM
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Mar-06-24 04:05PM
12:00PM
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levine James E.Chief Financial OfficerDec 17 '24Buy5.422,75214,90565,316Dec 18 04:37 PM
Levine James E.Chief Financial OfficerDec 18 '24Buy5.002,40012,00067,716Dec 18 04:37 PM
Levine James E.Chief Financial OfficerDec 16 '24Buy3.832,5649,82062,564Dec 18 04:37 PM
TANNENBAUM RENEE PDirectorDec 12 '24Buy3.4210,00034,22420,000Dec 16 05:00 PM
PACE GARY WDirectorDec 11 '24Buy2.60350,115910,2991,047,876Dec 12 04:05 PM
PACE GARY WDirectorDec 11 '24Buy2.6011,50029,9001,059,376Dec 12 04:05 PM